Adicet Bio (ACET) vs Celularity (CELU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Celularity (CELU) has outperformed Adicet Bio (ACET) over the past year, losing 26.8% versus a loss of 61.6%. Over five years, ACET leads with a -95.6% price change compared with -97.8% for CELU. Adicet Bio is the larger company by market cap ($52.5 million vs $50.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | CELU |
|---|---|---|
| Share price | $5.61 | $1.56 |
| Market cap | $52.52M | $50.62M |
| 1-day change | -2.26% | +6.85% |
| YTD return | -33.37% | +40.54% |
| 1-year return | -61.64% | -26.76% |
| 5-year return | -95.64% | -97.83% |
| EPS (TTM) | $-10.42 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $2.55 |
| 52-week low | $5.55 | $0.56 |
| Distance from 52-week high | -67.83% | -38.82% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +520.86% | — |
| Average volume | 174.39K | 3.89M |
| Shares outstanding | 9.36M | 32.45M |
| Employees | 102 | 115 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed ACET by 34.9 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
ACET vs CELU FAQ
Which is bigger, Adicet Bio or Celularity?
Adicet Bio (ACET) is larger, with a market capitalization of $52.52M compared with $50.62M for Celularity (CELU).
Which stock has performed better over the past year, ACET or CELU?
CELU returned -26.76% over the past 12 months, compared with -61.64% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Celularity in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.